Alec Stranahan
Stock Analyst at B of A Securities
(3.43)
# 2,629
Out of 4,479 analysts
20
Total ratings
66.67%
Success rate
14.52%
Average return
Main Sectors:
Top Industries:
10 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVAX Novavax | Maintains: Neutral | $12 → $18 | $12.73 | +41.40% | 3 | Jun 14, 2024 | |
| ERAS Erasca | Downgrades: Neutral | $11 → $6 | $2.44 | +145.90% | 1 | Jan 5, 2024 | |
| RVMD Revolution Medicines | Upgrades: Buy | $34 | $38.81 | -12.39% | 2 | Jan 5, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $118 → $140 | $182.27 | -23.19% | 3 | May 25, 2023 | |
| XNCR Xencor | Initiates: Buy | $42 | $19.02 | +120.82% | 1 | May 19, 2023 | |
| YMAB Y-mAbs Therapeutics | Maintains: Neutral | $6 → $12 | $11.83 | +1.44% | 4 | May 15, 2023 | |
| DAWN Day One Biopharmaceuticals | Downgrades: Underperform | $34 → $9 | $13.58 | -33.73% | 2 | Apr 25, 2023 | |
| TGTX TG Therapeutics | Maintains: Underperform | $5 → $6 | $18.15 | -66.94% | 2 | Dec 29, 2022 | |
| HOOK HOOKIPA Pharma | Downgrades: Underperform | $6 → $0.5 | $0.63 | -20.42% | 1 | Dec 2, 2022 | |
| SWTX SpringWorks Therapeutics | Initiates: Buy | $45 | $38.53 | +16.79% | 1 | Dec 1, 2022 |
Novavax
Jun 14, 2024
Maintains: Neutral
Price Target: $12 → $18
Current: $12.73
Upside: +41.40%
Erasca
Jan 5, 2024
Downgrades: Neutral
Price Target: $11 → $6
Current: $2.44
Upside: +145.90%
Revolution Medicines
Jan 5, 2024
Upgrades: Buy
Price Target: $34
Current: $38.81
Upside: -12.39%
Krystal Biotech
May 25, 2023
Maintains: Buy
Price Target: $118 → $140
Current: $182.27
Upside: -23.19%
Xencor
May 19, 2023
Initiates: Buy
Price Target: $42
Current: $19.02
Upside: +120.82%
Y-mAbs Therapeutics
May 15, 2023
Maintains: Neutral
Price Target: $6 → $12
Current: $11.83
Upside: +1.44%
Day One Biopharmaceuticals
Apr 25, 2023
Downgrades: Underperform
Price Target: $34 → $9
Current: $13.58
Upside: -33.73%
TG Therapeutics
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $18.15
Upside: -66.94%
HOOKIPA Pharma
Dec 2, 2022
Downgrades: Underperform
Price Target: $6 → $0.5
Current: $0.63
Upside: -20.42%
SpringWorks Therapeutics
Dec 1, 2022
Initiates: Buy
Price Target: $45
Current: $38.53
Upside: +16.79%